5/5 🌟 Why It Matters:
First evidence of TA in humans! This work rethinks DMD treatment, showing mRNA decay itself can drive genetic compensation. Kudos to 1st Lara!
@DouglasAdamoski

@TJ_ThomasJuan
& team!
@MPI_HLR
🎉 #RareDisease

4/5 🏥 Therapeutic Implications:
This TA mechanism opens new avenues: ASOs/ribozymes could enhance utrophin to compensate for dystrophin. Surprisingly, current exon-skipping therapies (e.g., eteplirsen) might reduce utrophin. #DrugDevelopment

3/5 💡 Key Experiments:
Splice-switching ASOs skipped exons, creating PTCs and raising utrophin levels.
Restoring the reading frame in patient cells reduced utrophin, showing TA’s role.
Self-cleaving ribozymes in minigenes also triggered utrophin. #ASO #RNA

2/5 🧪 How does it work?
By introducing premature stop codons (PTCs) in DMD mRNA, we induced mRNA decay via nonsense-mediated decay (NMD). This decay signals cells to boost UTRN (utrophin) transcription. Blocking NMD reversed utrophin upregulation! #GeneTherapy #CRISPR